Neurology
Conference Coverage
Abuse rate of gabapentin, pregabalin far below that of opioids
SAN ANTONIO – “Both gabapentin and pregabalin are abused but at rates that are 6-56 times less frequent than for opioid analgesics,” wrote Dr....
From the Journals
A/T/N system predicts cognitive decline
A test of the new A/T/N research model of dementia predicted rates of cognitive decline within its subgroups over a period of nearly 5 years.
From the Journals
Cognitive decline sped up after CHD
The acceleration in cognitive decline persisted for years after incident CHD.
From the Journals
Pediatric-onset MS may slow information processing in adulthood
Scores on the Symbol Digit Modalities Test begin to diverge after age 30 years between MS patients depending on age of onset.
Conference Coverage
Estimated prevalence of OSA in the Americas stands at 170 million
The United States has the greatest burden of OSA in the Americas, with an estimated 54 million cases.
Feature
Opioid prescriptions declined 33% over 5 years
The number of opioid prescriptions decreased 33% nationally from 2013 to 2018, according to the new report from the American Medical Association...
News
Treatment for hepatitis C reduces risk of Parkinson’s disease
Data support the hypothesis that hepatitis C virus infection is a risk factor for incident Parkinson’s disease.
News from the FDA/CDC
Stewart Tepper: Emgality approval ‘very exciting’
The treatment binds to calcitonin gene-related peptide and is the first therapy to reduce the frequency of episodic cluster headache attacks.
Conference Coverage
DOACs surpass warfarin in low-weight AFib patients
SAN FRANCISCO – Data from 21,000 Korean AFib patients weighing 60 kg or less showed DOACs had better efficacy and safety than did warfarin.
Conference Coverage
Meta-analysis finds no link between PPI use and risk of dementia
SAN DIEGO – In the absence of randomized trial evidence, a PPI prescribing approach based on appropriate use appears sufficient.
Conference Coverage
Low baseline heart rate may not increase cardiac risk when starting fingolimod
SEATTLE – First-dose cardiac events with fingolimod are rare, regardless of whether first-dose observations occur in clinic or at home.